|
US6756038B1
(en)
*
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
|
DE10048710A1
(de)
*
|
1999-09-27 |
2001-10-04 |
Gabriele Pecher |
Pharmazeutische Zusammensetzung zur Behandlung und Prophylaxe von humanen Tumoren, die das Tumorantigen Muzin und/oder das Carcinoembryonale Antigen (CEA) exprimieren und ihre Verwendung
|
|
CA2388337C
(en)
*
|
1999-10-22 |
2013-01-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
EP1286693A4
(en)
|
2000-06-02 |
2005-07-13 |
Univ Connecticut Health Ct |
COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY
|
|
AU2001278330A1
(en)
*
|
2000-07-31 |
2002-02-13 |
Aventis Pasteur Limited |
Modified CEA and uses thereof
|
|
US7025968B2
(en)
|
2000-08-30 |
2006-04-11 |
Chemocentryx, Inc. |
CMV vaccines
|
|
EP1320620B1
(en)
|
2000-09-25 |
2015-01-21 |
The Regents Of The University Of Michigan |
Production of viral vectors
|
|
CA2437201C
(en)
|
2001-02-02 |
2008-11-18 |
Chemocentryx, Inc. |
Methods and compositions useful for stimulating an immune response
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
US7414032B2
(en)
|
2001-06-25 |
2008-08-19 |
Immunofrontier, Inc. |
Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
|
|
AU2003301021C1
(en)
|
2002-12-16 |
2010-02-18 |
Globelmmune, Inc. |
Yeast-based vaccines as immunotherapy
|
|
WO2005026370A2
(en)
*
|
2003-09-05 |
2005-03-24 |
Sanofi Pasteur Limted. |
Multi-antigen vectors for melanoma
|
|
KR101162970B1
(ko)
*
|
2003-10-08 |
2012-07-12 |
테리온 바이오로직스, 인크. |
변형된 ｃｅａ/ｂ7 벡터
|
|
WO2005046622A2
(en)
|
2003-11-12 |
2005-05-26 |
Therion Biologics Corporation |
Custom vectors for treating and preventing pancreatic cancer
|
|
US8933041B2
(en)
*
|
2003-11-12 |
2015-01-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
System for treating and preventing breast cancer
|
|
WO2005068640A2
(en)
*
|
2003-12-23 |
2005-07-28 |
Aventis Pasteur, Inc. |
Modified ksa and uses thereof
|
|
CN1976946A
(zh)
*
|
2004-07-03 |
2007-06-06 |
财团法人牧岩生命工学研究所 |
诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用
|
|
US7785875B2
(en)
|
2004-07-03 |
2010-08-31 |
Mogam Biotechnology Research Institute |
Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
|
|
ES2313807B1
(es)
*
|
2005-07-30 |
2009-12-23 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.
|
|
EP1792996A1
(en)
*
|
2005-12-01 |
2007-06-06 |
Consejo Superior de Investigaciones Cientificas |
Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
NZ584042A
(en)
*
|
2007-10-18 |
2012-09-28 |
Bn Immunotherapeutics Inc |
Use of mva to treat prostate cancer
|
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
ES2547654T3
(es)
*
|
2008-10-31 |
2015-10-07 |
Tremrx, Inc. |
Vacunación con vectores poxvirales mediante alteración mecánica epidérmica
|
|
CA2759013C
(en)
|
2009-04-17 |
2021-10-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy compositions against cancer and methods
|
|
RU2642300C2
(ru)
|
2011-08-17 |
2018-01-24 |
Глоубиммьюн, Инк. |
Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
CN105431157A
(zh)
|
2013-06-14 |
2016-03-23 |
普赛奥克苏斯治疗公司 |
用于b型腺病毒的给药方案及制剂
|
|
TR201802728T4
(tr)
|
2013-10-25 |
2018-03-21 |
Psioxus Therapeutics Ltd |
Heterolog genlerle donatılmış onkolitik adenovirüsler.
|
|
MX377258B
(es)
*
|
2013-11-28 |
2025-03-07 |
Bavarian Nordic As |
Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria.
|
|
JP5917626B2
(ja)
*
|
2014-07-28 |
2016-05-18 |
トレムアールエックス， インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
|
AU2016205208A1
(en)
|
2015-01-09 |
2017-07-06 |
Etubics Corporation |
Methods and compositions for ebola virus vaccination
|
|
JP6647315B2
(ja)
*
|
2015-01-09 |
2020-02-14 |
イーチュービクス コーポレイション |
組み合わせ免疫療法のための方法および組成物
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
PE20180241A1
(es)
*
|
2015-04-30 |
2018-01-31 |
Psioxus Therapeutics Ltd |
Adenovirus oncolitico que codifica una proteina b7
|
|
KR102857666B1
(ko)
|
2015-12-17 |
2025-09-10 |
아카미스 바이오 리미티드 |
항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
|
|
SG11201808058PA
(en)
*
|
2016-03-18 |
2018-10-30 |
Nantcell Inc |
Multimodal vector for dendritic cell infection
|
|
KR20200138418A
(ko)
*
|
2016-05-27 |
2020-12-09 |
이투빅스 코포레이션 |
네오에피토프 백신 조성물 및 이의 사용 방법
|
|
AU2017320776B2
(en)
|
2016-08-29 |
2024-10-10 |
Akamis Bio Limited |
Adenovirus armed with bispecific T cell activator
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
US11844824B2
(en)
*
|
2018-03-06 |
2023-12-19 |
Pepvax, Inc. |
Nucleic acid molecules and methods of using the same
|
|
WO2020061203A1
(en)
|
2018-09-21 |
2020-03-26 |
Nantcell, Inc. |
Methods and compositions for modulating myeloid-derived suppressor cells
|
|
GB202010095D0
(en)
*
|
2020-07-01 |
2020-08-12 |
Tcer Ab |
Immunotherapy
|